AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
estrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| estrogens | 3188 | 53-16-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.579 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.436 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 53.951 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 41.591 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 2.440 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 4.060 | % | High | 1 |
| herg | hERG pIC50 | 4.610 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 79.068 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 36.644 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 2.390 | % | High | 1 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKDC,STK33,TEK,TGFBR1 | 26 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.873 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 344.350 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 3.130 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.849 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 5.900 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 232.809 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 28.330 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 3.130 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 8.204 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 21, 1979 | FDA | WATSON LABS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Menopausal symptoms | 43.49 | 15.71 | 13 | 5024 | 3065 | 90620345 |
| Hot flush | 41.77 | 15.71 | 31 | 5006 | 59457 | 90563953 |
| Eosinophilic pneumonia acute | 39.85 | 15.71 | 9 | 5028 | 706 | 90622704 |
| Thyrotoxic periodic paralysis | 26.41 | 15.71 | 4 | 5033 | 32 | 90623378 |
| Phyllodes tumour | 22.83 | 15.71 | 4 | 5033 | 84 | 90623326 |
| Ophthalmic vein thrombosis | 22.75 | 15.71 | 5 | 5032 | 346 | 90623064 |
| Hypertrophic cardiomyopathy | 21.37 | 15.71 | 7 | 5030 | 2221 | 90621189 |
| Feeling abnormal | 20.77 | 15.71 | 35 | 5002 | 167200 | 90456210 |
| Disease recurrence | 20.73 | 15.71 | 17 | 5020 | 37636 | 90585774 |
| Blood creatine phosphokinase increased | 20.08 | 15.71 | 16 | 5021 | 34007 | 90589403 |
| Keratoconus | 18.78 | 15.71 | 3 | 5034 | 35 | 90623375 |
| Muscle necrosis | 18.39 | 15.71 | 5 | 5032 | 839 | 90622571 |
| Vaginal haemorrhage | 16.96 | 15.71 | 14 | 5023 | 31257 | 90592153 |
| Ovarian haemorrhage | 16.69 | 15.71 | 4 | 5033 | 407 | 90623003 |
| Wrong technique in product usage process | 16.30 | 15.71 | 20 | 5017 | 71551 | 90551859 |
| Incorrect dose administered | 16.30 | 15.71 | 21 | 5016 | 78909 | 90544501 |
| Injection site pain | 16.05 | 15.71 | 32 | 5005 | 173667 | 90449743 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Menopausal symptoms | 51.47 | 17.20 | 13 | 4056 | 2488 | 110582742 |
| Eosinophilic pneumonia acute | 35.98 | 17.20 | 9 | 4060 | 1656 | 110583574 |
| Hot flush | 26.76 | 17.20 | 21 | 4048 | 66015 | 110519215 |
| Ophthalmic vein thrombosis | 26.29 | 17.20 | 5 | 4064 | 256 | 110584974 |
| Phyllodes tumour | 24.13 | 17.20 | 4 | 4065 | 92 | 110585138 |
| Hypertrophic cardiomyopathy | 21.80 | 17.20 | 7 | 4062 | 3156 | 110582074 |
| Thyrotoxic periodic paralysis | 21.08 | 17.20 | 4 | 4065 | 202 | 110585028 |
| Disease recurrence | 19.75 | 17.20 | 17 | 4052 | 60767 | 110524463 |
| Injection site pain | 17.86 | 17.20 | 27 | 4042 | 177895 | 110407335 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03CA07 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Natural and semisynthetic estrogens, plain |
| ATC | G03CC04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Estrogens, combinations with other drugs |
| MeSH PA | D004967 | Estrogens |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50114 | estrogen |
| CHEBI has role | CHEBI:50646 | bone density conservation agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
G03CA Natural and semisynthetic estrogens, plain 7 drugs
G03CC Estrogens, combinations with other drugs 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Contraception | indication | 13197004 | |
| Acne vulgaris | indication | 88616000 | |
| Chemotherapy-induced nausea and vomiting | indication | 236084000 | |
| Prevention of Post-Operative Nausea and Vomiting | indication | ||
| Prevention of Radiation-Induced Nausea and Vomiting | indication | ||
| Excessive vomiting in pregnancy | off-label use | 14094001 | |
| Amenorrhea | off-label use | 14302001 | DOID:13938 |
| Female hypogonadism syndrome | off-label use | 16041008 | |
| Polycystic ovaries | off-label use | 69878008 | |
| Menopausal flushing | off-label use | 198436008 | |
| Dysmenorrhea | off-label use | 266599000 | |
| Abnormal uterine bleeding unrelated to menstrual cycle | off-label use | 312984006 | |
| Menorrhagia | off-label use | 386692008 | |
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
| Hypocalcemia | contraindication | 5291005 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Depressive disorder | contraindication | 35489007 | |
| Chloasma | contraindication | 36209000 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Dementia | contraindication | 52448006 | |
| Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Benign mammary dysplasia | contraindication | 57993004 | |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Hepatic failure | contraindication | 59927004 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Breast lump | contraindication | 89164003 | |
| Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
| Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Endometriosis | contraindication | 129103003 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Mammography abnormal | contraindication | 168750009 | |
| Angina pectoris | contraindication | 194828000 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cholestasis of pregnancy | contraindication | 235888006 | |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Chorea | contraindication | 271700006 | |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Functional visual loss | contraindication | 313165001 | |
| Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
| Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Family history of malignant neoplasm of breast | contraindication | 429740004 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication | ||
| Major Surgery with Prolonged Post-Operative Immobilization | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.13 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | AGONIST | EC50 | 9.15 | CHEMBL | CHEMBL | |||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.55 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.06 | DRUG MATRIX | |||||
| Estrogen receptor beta | Nuclear hormone receptor | EC50 | 8.68 | CHEMBL | |||||
| Aldose reductase | Enzyme | IC50 | 4.51 | CHEMBL | |||||
| Aromatase | Enzyme | Ki | 5.60 | CHEMBL | |||||
| Corticosteroid-binding globulin | Secreted | Ki | 5 | CHEMBL | |||||
| Steryl-sulfatase | Enzyme | IC50 | 4.29 | CHEMBL | |||||
| Sex hormone-binding globulin | Secreted | Kd | 8.18 | CHEMBL | |||||
| Estradiol 17-beta-dehydrogenase 1 | Enzyme | Ki | 8.52 | CHEMBL | |||||
| Aldo-keto reductase family 1 member B10 | Enzyme | IC50 | 5.80 | CHEMBL | |||||
| Alpha-synuclein | Transporter | IC50 | 4.03 | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.18 | DRUG MATRIX | |||||
| Progesterone receptor | Transcription factor | Ki | 5.68 | DRUG MATRIX | |||||
| Androgen receptor | Transcription factor | Ki | 5.11 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4022631 | VUID |
| N0000146811 | NUI |
| D00067 | KEGG_DRUG |
| 4018489 | VANDF |
| 4022631 | VANDF |
| C0236379 | UMLSCUI |
| CHEBI:17263 | CHEBI |
| J3Z | PDB_CHEM_ID |
| CHEMBL1405 | ChEMBL_ID |
| DB00655 | DRUGBANK_ID |
| D004970 | MESH_DESCRIPTOR_UI |
| 5870 | PUBCHEM_CID |
| 2818 | IUPHAR_LIGAND_ID |
| 407 | INN_ID |
| 2DI9HA706A | UNII |
| 4103 | RXNORM |
| 2450 | MMSL |
| 4688 | MMSL |
| d00534 | MMSL |
| 001270 | NDDF |
| 51775003 | SNOMEDCT_US |
| 90017009 | SNOMEDCT_US |
| 2DI9HA706A | INXIGHT DRUGS |
Pharmaceutical products:
None